Lowering of cholesterol to reduce the rate of IHD has been associated with increased deaths from suicide and accidents (Engelberg, 1992) . Elliott (Journal, June 1993, 162, 818â€"825) suggests that the overall result of diminished brain cholesterol would be reduced 5-HT (serotonin) activity by increased pre-synaptic 5-HT uptake or decreased post-synaptic transmission.
A loweringof total plasmacholesterolon recovery from depression might therefore inhibit the facili tation of 5-HT transmission generally considered to be the result of antidepressant treatment, if it were mirrored in the brain, but the cholesterol content of HDL may be more important for brain function. In our study there was no significant change in HDL on recovery (mean Â±s.d.:39.9Â±10.3 v. 38.5Â±10.1%) .
The activity of the 5-HT pump is increased by low cholesterol, as is Na/K ATPase activity (Papahajopoulos eta!, 1973) . Red-cell Na/K ATPase is known to be low in depressed patients, and to increase on recovery (Naylor et a!, 1980) . Further studies of cholesterol levels in depression with con comitant observation of 5-HT receptor function, optimally by provocation tests, would be of value in clarifying the relationships of cholesterol to 5-HT activity, Na/K ATPase activity, and the risk of IHD in depressive illness. for my earlier contention (Hsu, 1988 ) that â€oe¿ for those who recovered from anorexia nervosa, normal weight bulimia nervosa (not major depression) is the most common diagnosisâ€•. The preliminary data from our own long-term follow-up study also indi cated that eating disorder not otherwise specified (ED NOS) is the most common diagnosis, not buli mia nervosa (Hsu et a!, 1992) . From the data pre sented by Windauer et a!, I would think that ED NOS is also the most common diagnosis among those who no longer meet criteria for anorexia nervosa. syndromes. Moreover, the groups were also similar with respect to DSMâ€"IIIâ€"R diagnoses, ethnicity and socio-economic class, differing only, as expected, in terms of their histories of substance use. We also examined the morbid risk of psychiatric illness in first-degree relatives, using maternal inter views and RDCâ€"FHcriteria, and Weinberg's shorter method of age correction. Cannabis positive cases had a significantly higher familial morbid risk of schizophrenia than the controls (7.1% v.0.7%; odds ratio= 10.2; 95% CI 1.12â€"234, P=0.02), but similar rates for other conditions.
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We agree with the author's conclusion that there is little evidence to support the concept of a â€˜¿ cannabis psychosis'. Furthermore, we propose that psychosis occurring in the context of cannabis use may be par ticularly likely in those with a genetic predisposition to psychotic illness; cannabis use may trigger a â€˜¿ func tional' psychosis in those with a psychotic diathesis, rather than producing a specific â€˜¿ cannabis psychosis' denovo.
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with â€˜¿ functional' unipolar depression (Settle & Settle, 1984) or bipolar disorder (Lebegue, 1987) , cases of mania induced by fluoxetine in patients with â€˜¿ or ganic' mood disorders have not been reported. The following case report describes a patient with post stroke depression (PSD), who developed mania three weeks after starting low doses of fluoxetine. Nortriptyline, trazodone and electroconvulsive therapy have all been reported to be effective and safe for treating PSD without the induction of mania (Robinson&Starkstein, 1990) . Less is known about the efficacy and side-effects offluoxetine and other selective serotonin-reuptake inhibitors in the treatment of organic mood disorders, although Morris (1991) has recently reported recurrent orgasmic sexual experiences induced by fluoxetine in a patient with PSD.
Since post-stroke bipolar affective disorder has mainly been reported after subcortical right hemisphere lesions (Starkstein eta!, 1991) , it is poss ible that in our casefluoxetine may have precipitated a latent bipolar disorder. Therefore, further studies are needed to provide information on fluoxetine's safety profile in patients with PSD and right hemisphere damage.
